Moderna
Generated by Meeveem AI
"Pioneers in mRNA medicines transforming how diseases are treated and prevented"
About Moderna
Moderna develops messenger RNA medicines to prevent and treat disease, combining a shared technology platform with research, clinical development and manufacturing. Its work spans infectious disease vaccines, oncology and rare disease therapeutics. At September 2026, it reported five approved products covering COVID-19, respiratory syncytial virus and influenza, including a combined flu and COVID-19 vaccine.
Founded in 2010 and headquartered in Cambridge, Massachusetts, the company reported approximately 4,700 full-time employees in 18 countries at the end of 2025. Its UK operations include the Moderna Innovation and Technology Centre at Harwell in Oxfordshire, opened in 2025 for research and manufacturing. Teams support both commercial medicines and investigational treatments moving through clinical trials.
Learning across the company
New employees join Moderna ONE, an onboarding programme introducing the company's science and ways of working. Ongoing development includes a structured technology curriculum, scientific learning resources and management and leadership training. The AI Academy helps employees apply artificial intelligence to their work, supported by practical skills training.
4700
Team Members
2010
Founded
Biotechnology
Sector
On-Site
Work Environment